Literature DB >> 16462508

Does breast size affect the scatter dose to the ipsilateral lung, heart, or contralateral breast in primary breast irradiation using intensity-modulated radiation therapy (IMRT)?

Ajay K Bhatnagar1, Dwight E Heron, Melvin Deutsch, Edward Brandner, Andrew Wu, Shalom Kalnicki.   

Abstract

PURPOSE: To evaluate the relationship between the primary breast volume and dose received by the ipsilateral lung, heart (for left-breast cancers), and contralateral breast during primary breast irradiation using intensity-modulated radiation therapy (IMRT). METHODS AND MATERIALS: Sixty-five patients with breast carcinoma were treated using 6-MV photons with IMRT technique using the Eclipse Planning System following breast conserving surgery. All patients had a treatment planning CT scan. The primary breast, ipsilateral lung, and heart were contoured on the axial CT slices. The primary breast volume was calculated using the Eclipse Planning System. The mean ipsilateral lung and heart doses were obtained from the dose-volume histogram. The contralateral breast dose was measured using paired thermoluminescent dosimeters (TLDs) placed on the patient's contralateral breast, 4 cm from the center of the medial border of the primary breast irradiation field.
RESULTS: The mean dose delivered with photons to the primary breast for all patients was 49.97 Gy. The mean volume of the primary irradiated breast was 1167.9 cc. As a percentage, the mean ipsilateral lung, heart, and contralateral breast doses were 11.2%, 6.1%, and 7.2%, respectively. The primary breast volume positively correlated with the contralateral breast dose (P < 0.0005). There was no significant correlation between the breast volume and the ipsilateral lung or heart dose (P = 0.463 and 0.943, respectively).
CONCLUSION: This study suggests that the primary breast size significantly affects the scatter dose to the contralateral breast but not the ipsilateral lung or heart dose when using IMRT for breast irradiation.

Entities:  

Mesh:

Year:  2006        PMID: 16462508     DOI: 10.1097/01.coc.0000198743.80991.15

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

1.  Assessment of contralateral mammary gland dose in the treatment of breast cancer using accelerated hypofractionated radiotherapy.

Authors:  Maria Tolia; Kalliopi Platoni; Andreas Foteineas; Maria-Aggeliki Kalogeridi; Anna Zygogianni; Nikolaos Tsoukalas; Mariangela Caimi; Niki Margari; Maria Dilvoi; Panagiotis Pantelakos; John Kouvaris; Vassilis Kouloulias
Journal:  World J Radiol       Date:  2011-09-28

2.  Tangential beam IMRT versus tangential beam 3D-CRT of the chest wall in postmastectomy breast cancer patients: a dosimetric comparison.

Authors:  Volker Rudat; Abdul Aziz Alaradi; Adel Mohamed; Khaled Ai-Yahya; Saleh Altuwaijri
Journal:  Radiat Oncol       Date:  2011-03-21       Impact factor: 3.481

3.  Reduction of Dose to the Contralateral Breast by Superflab Use in Radiation Therapy for Mammary Carcinomas

Authors:  Akanksha Solanki; Athiyaman M; Hemalatha A; H S Kumar
Journal:  Asian Pac J Cancer Prev       Date:  2017-04-01

4.  Breast size impact on adjuvant radiotherapy adverse effects and dose parameters in treatment planning.

Authors:  Ivica Ratosa; Aljasa Jenko; Irena Oblak
Journal:  Radiol Oncol       Date:  2018-08-02       Impact factor: 2.991

5.  Dosimetric evaluation of the heart and left anterior descending artery dose in radiotherapy for Japanese patients with breast cancer.

Authors:  Osamu Tanaka; Kousei Ono; Takuya Taniguchi; Chiyoko Makita; Masayuki Matsuo
Journal:  J Radiat Res       Date:  2020-01-23       Impact factor: 2.724

6.  A comparative dosimetric study for treating left-sided breast cancer for small breast size using five different radiotherapy techniques: conventional tangential field, filed-in-filed, tangential-IMRT, multi-beam IMRT and VMAT.

Authors:  Guang-Hua Jin; Li-Xin Chen; Xiao-Wu Deng; Xiao-Wei Liu; Ying Huang; Xiao-Bo Huang
Journal:  Radiat Oncol       Date:  2013-04-15       Impact factor: 3.481

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.